Minerva Neurosciences adds Dr. Inderjit Kaul to board

Minerva Neurosciences, Inc. (NASDAQ: NERV) appointed Dr. Inderjit Kaul to its board of directors, the clinical-stage biopharmaceutical company announced. Dr. Kaul will also serve as a consultant for the clinical development of roluperidone, the company's treatment for negative symptoms in schizophrenia patients.

Dr. Kaul currently serves as Chief Medical Officer at Draig Therapeutics. He previously held the position of Senior Vice President of Late-Stage Clinical Development, Neuropsychiatry at Bristol Myers Squibb from March 2024 to May 2025, where he oversaw product development and clinical strategy for Cobenfy for multiple indications including schizophrenia.

From March 2020 to March 2024, Dr. Kaul led development of a muscarinic agonist for acute schizophrenia treatment at Karuna Therapeutics, resulting in FDA approval of Cobenfy. He holds an M.D. and an MPH from Harvard University.

The appointment follows Minerva's announcement last month of raising up to $200 million in private placement funding. The company plans to use the funds for a confirmatory Phase 3 trial of roluperidone for negative symptoms in schizophrenia patients, resubmission of its New Drug Application, and preparation for potential U.S. commercial launch.

"Dr. Kaul is an experienced and successful global drug development leader, with expertise in regulatory, clinical and commercialization operations," said Dr. Remy Luthringer, Executive Chairman and CEO of Minerva Neurosciences.

According to the company, approximately 50% to 60% of people with schizophrenia experience at least one primary negative symptom, and no FDA-approved treatments specifically target these symptoms. The FDA has acknowledged this as an unmet medical need.

You May Also Be Interested In

• Jefferies Upgrades Minerva Neurosciences (NERV) to Buy
• Elutia secures $15M loan from Avenue Capital for NXT-41x launch
• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral